Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
7.50
-0.01 (-0.13%)
At close: Jun 27, 2025, 4:00 PM
7.18
-0.32 (-4.27%)
After-hours: Jun 27, 2025, 7:42 PM EDT
Enanta Pharmaceuticals Revenue
Enanta Pharmaceuticals had revenue of $14.93M in the quarter ending March 31, 2025, a decrease of -12.48%. This brings the company's revenue in the last twelve months to $64.46M, down -11.55% year-over-year. In the fiscal year ending September 30, 2024, Enanta Pharmaceuticals had annual revenue of $67.64M, down -14.61%.
Revenue (ttm)
$64.46M
Revenue Growth
-11.55%
P/S Ratio
2.38
Revenue / Employee
$492,084
Employees
131
Market Cap
160.32M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 67.64M | -11.57M | -14.61% |
Sep 30, 2023 | 79.20M | -6.96M | -8.07% |
Sep 30, 2022 | 86.16M | -10.91M | -11.24% |
Sep 30, 2021 | 97.07M | -25.40M | -20.74% |
Sep 30, 2020 | 122.47M | -82.72M | -40.31% |
Sep 30, 2019 | Pro | Pro | Pro |
Sep 30, 2018 | Pro | Pro | Pro |
Sep 30, 2017 | Pro | Pro | Pro |
Sep 30, 2016 | Pro | Pro | Pro |
Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ENTA News
- 17 days ago - Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus - Business Wire
- 4 weeks ago - Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - Business Wire
- 5 weeks ago - Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting - Business Wire
- 6 weeks ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025 - Business Wire
- 2 months ago - Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025 - Business Wire
- 3 months ago - Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - Business Wire
- 3 months ago - Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium - Business Wire
- 4 months ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024 - Business Wire